Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Organicell Regenerative Medicine Inc (OP: OCEL )

2.750 UNCHANGED
Last Price Updated: 3:51 PM EST, Mar 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 2.750
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 2.750
Today's Range 2.750 - 2.750
52wk Range 0.0051 - 3.540
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
RETRANSMISSION: Organicell Regenerative Medicine Rebranding to ZEO ScientifiX
Via ACCESSWIRE
Organicell Announces 1-for-200 Reverse Stock Split
Via ACCESSWIRE

Performance

YTD
+169.61%
+169.61%
1 Month
N/A
N/A
3 Month
N/A
N/A
6 Month
N/A
N/A
1 Year
+31509.20%
+31509.20%

More News

Read More
Organicell Reports Interim Results of Phase 1/2A Research Program
Via ACCESSWIRE
1847 Holdings And 3 Other Stocks Under $1 Insiders Are Buying
Via Benzinga
Alset And 2 Other Stocks Under $2 Insiders Are Aggressively Buying
Via Benzinga
Organicell Starts Enrolling Long COVID Trial
Via ACCESSWIRE
Organicell Activates COPD Trial at Mayo Clinic
Via ACCESSWIRE
Organicell Regenerative Medicine, Inc. Announces Additions to Board of Directors
Via ACCESSWIRE
Organicell Regenerative Medicine, Inc. Announces Expansion into Health and Beauty Market
Via Benzinga
Organicell Welcomes Howard Golub, MD, PhD As Its New EVP/CSO
Via ACCESSWIRE
Organicell Welcomes Harry Leider, MD, MBA as its New CEO
Via ACCESSWIRE
Recent Report Shows That Extracellular Vesicles Might Also Be Key To Stopping COVID, Colds, And Other Nasal Viruses
Via News Direct
Exposures COVID-19 Product Safety
Recent Report Shows That Extracellular Vesicles Might Also Be Key To Stopping COVID, Colds, And Other Nasal Viruses
Via TheNewswire.com
Exposures COVID-19 Product Safety
Recent Report Shows That Extracellular Vesicles Might Also Be Key To Stopping COVID, Colds, And Other Nasal Viruses
Via Benzinga
Organicell Regenerative Medicine, Inc. Responds to Recent Promotional Activities Pursuant to OTC Markets Request
Via ACCESSWIRE
One in Five Americans Who Have Been Infected With the Virus Said to Have Long COVID
Via FinancialNewsMedia
Exposures COVID-19
Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027
Via FinancialNewsMedia
Organicell Regenerative Medicine Broadens Access to Valued Business Expertise and Relationship With New Additions to Board of Directors
Via Benzinga
Organicell Regenerative Medicine, Inc. Announces Expansion of Management Team
Via ACCESSWIRE
Pharma Company Organicell Partners With Beauty Health Focusing On Aging & Inflammation Signs
Via Benzinga
Organicell Regenerative Medicine, Inc. Announces Expansion into Health and Beauty Market
Via ACCESSWIRE
BeautyHealth’s Hydrafacial Announces Partnership to Develop Breakthrough Exosome Booster
From BeautyHealth
Via Business Wire
Organicell Regenerative Medicine, Inc. Secures Additional $11 Million in Financing in Preparation for Clinical Trial Enrollment
Via ACCESSWIRE
Organicell Regenerative Medicine, Inc. Engages Law Firm McDermott Will & Emery
Via ACCESSWIRE
Organicell Regenerative Medicine, Inc. Closes $5.5 Million Funding Round
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.